GI Adverse Events Up With GLP-1 Receptor Agonists

Share this content:
GI Adverse Events Up With GLP-1 Receptor Agonists
GI Adverse Events Up With GLP-1 Receptor Agonists

TUESDAY, Nov. 15, 2016 (HealthDay News) -- Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are associated with increased risk of gastrointestinal adverse events (AEs), with risk varying based on dose, background medications, and type of GLP-1 RA, according to research published online Nov. 9 in Diabetes, Obesity and Metabolism.

Karolin Bettge, from St. Josef Hospital in Bochum, Germany, and colleagues conducted a systematic literature review and selected 32 phase 3 clinical trials with GLP-1 RAs. They analyzed the proportion of patients reporting nausea, vomiting, or diarrhea for different doses and glucose-lowering background medications.

The researchers observed a dose-dependent risk for nausea for long-acting agents and across all GLP-1 RAs (P = 0.0063 and 0.0017, respectively); a similar trend was seen for vomiting (P = 0.23). There was a dose-dependent risk for diarrhea (P = 0.031). More nausea and vomiting were seen for background treatment with metformin (P = 0.04 and 0.0009, respectively). Less nausea and less diarrhea were seen for lixisenatide versus exenatide (twice/day). The risk was similar for dulaglutide and liraglutide, while less risk was seen for exenatide and albiglutide versus liraglutide. Compared with short-acting agents, long-acting GLP-1 RAs correlated with less nausea and vomiting but more diarrhea.

"GLP-1 RAs are associated with gastrointestinal AEs that are related to dose and background medications (especially metformin), and may vary in a compound-specific manner," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Actemra to Treat Giant Cell Arteritis

FDA Approves Actemra to Treat Giant Cell Arteritis

New indication provides the first FDA-approved therapy specific to this type of vasculitis

Trends in Teen Binge Drinking Still Raise Concerns

Trends in Teen Binge Drinking Still Raise Concerns

Even though frequent binge drinking among adolescents has dropped in past 25 years

ATS: First Abx Rx Doesn't Work for 25 of Pneumonia Cases

ATS: First Abx Rx Doesn't Work for ~25% ...

One in four adult patients do not respond to initial prescription of antibiotic treatment

is free, fast, and customized just for you!

Already a member?

Sign In Now »